Products for Research Use Only
RegisterLogin

Concizumab ELISA Kit

CAT: 1358-DY403028Size: 96 TestsDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:1358-DY403028Size:96 Tests
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Background
Concizumab (mAb 2021) is a high-affinity, humanized, monoclonal IgG4 antibody (mAb) developed by Novo Nordisk A/S. It was directed against the Kunitz-2 domain of human tissue factor (TF) pathway inhibitor (TFPI), designed to target and selectively block the factor X (FX) a (FXa) binding site of TFPI. As a mAb, concizumab has the advantage of being administered subcutaneously, and exhibits good solubility and stability, allowing administration as a liquid formulation via a ready- and easy-to-use portable pen device. Phase 2 trials of concizumab are ongoing for Haemophilia A and B. On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.
Description
PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human TFPI antigen has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Concizumab in the sample competitively binds to the pre-coated protein with biotin-labeled Concizumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Concizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Specifications
Concizumab
Product Name Alternative
Anti-TFPI, NN7415, mab2021, CAS: 1312299-39-0
Detection Method
Colorimetric
Assay Type
Quantitative
Sample Type
Plasma, Serum
Detection Range
0.31-5 μg/mL
Recovery
80-120%
Sensitivity
0.156 μg/ml
Shipping Conditions
2-8 °C
Storage Conditions
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition.
Notes
For Research Use Only.

Related Products

CatalogName
HY403026-01Research Grade Concizumab
DF943028Gevokizumab ELISA Kit
DF998018Ibalizumab ELISA Kit
DF998038Zanolimumab ELISA Kit
DY213028Namilumab ELISA Kit
DY286028Pertuzumab ELISA Kit
DY286038Trastuzumab ELISA Kit
DY035018Cabiralizumab ELISA Kit
DY353048Ganitumab ELISA Kit
DY353058Teprotumumab ELISA Kit

Alternative Products

CatalogName
GTR18872336Concizumab ELISA Kit
KBI1245KRIBIOLISA™ Concizumab ELISA
T77373-01Concizumab
CBA1042-01Concizumab Biosimilar
GTR18333621-01Concizumab Antibody
591765Concizumab (TFPI)
A2337-01Concizumab (Anti-TFPI)
047778TFPI (concizumab) discontinued
MBS1563489-01Research Grade Concizumab
E55B0511Concizumab (Reference antibody)

Popular Products